Warning: The NCBI web site requires JavaScript to function. more...
Effect of sepsis therapies on health-related quality of life.
Erickson SE, Martin GS.
Crit Care. 2008;12(1):109. Epub 2008 Jan 22.
Related citations
Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
Levi M.
Crit Care Med. 2003 Mar;31(3):984-5. Review. No abstract available.
Treating sepsis.
Wenzel RP.
N Engl J Med. 2002 Sep 26;347(13):966-7. No abstract available.
Drotrecogin alfa (activated) in severe sepsis.
LaRosa SP.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. No abstract available.
Risks and benefits of activated protein C treatment for severe sepsis.
Warren HS, Suffredini AF, Eichacker PQ, Munford RS.
N Engl J Med. 2002 Sep 26;347(13):1027-30. No abstract available.
Baillie JK, Murray G.
Recombinant human activated protein C sentenced to the death of a thousand cuts?
O'Brien JM.
Crit Care Med. 2007 Jun;35(6):1609-10. No abstract available.
A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care.
Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day AG.
Crit Care. 2007;11(6):R128. Erratum in: Crit Care. 2008;12(5):429.
Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.
Carlet J.
Crit Care Med. 2006 Feb;34(2):525-9. No abstract available.
Criteria for use of drotrecogin alfa.
Jacobi J.
Am J Health Syst Pharm. 2004 Jan 15;61(2):203-4; author reply 204-5. No abstract available.
Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS, Hydo LJ, Shou J, Eachempati SR.
Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.
Assessing the use of activated protein C in the treatment of severe sepsis.
Siegel JP.
N Engl J Med. 2002 Sep 26;347(13):1030-4. No abstract available.
Friedrich JO.
Management of sepsis.
Mackenzie AF, Bartelink AK.
N Engl J Med. 2007 Mar 15;356(11):1179; author reply 1181-2. No abstract available.
[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
Rustige J.
Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698; author reply 1699-70. German. No abstract available.
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
Friedrich JO, Adhikari NK, Meade MO.
Crit Care. 2006;10(6):427. No abstract available.
Severe sepsis and therapy with activated protein C.
Parrillo JE.
N Engl J Med. 2005 Sep 29;353(13):1398-400. No abstract available. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.
Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
Dasta JF, Cooper LM.
Pharmacotherapy. 2002 Dec;22(12 Pt 2):216S-222S. Review.
The efficacy of drotrecogin alfa depends on severity of illness.
Deans KJ, Minneci PC, Eichacker PQ, Natanson C.
Crit Care Med. 2004 Nov;32(11):2347. No abstract available.
Drotrecogin alfa (activated) administration: too many subgroups.
Crit Care Med. 2003 Oct;31(10):2564; author reply 2564-5. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on